Skip to main content


Swearing In New NIAMS Director

Posted on by

Francis Collins and Lindsey Criswell
Lindsey Criswell (right) has joined the NIH family as director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Due to the pandemic, her swearing-in ceremony was held virtually on February 16, 2021.

A Song for Steve

Posted on by

Steve Katz, director of NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases, recently passed away. It was my honor to offer a tribute in song to my good friend Steve at the 30th annual meeting of his colleagues at the American Contact Dermatitis Society (ACDS) in Washington, D.C. The event was held on February 28, 2019. Credit: Boris D. Lushniak.

NIH Research Leads to New Rheumatoid Arthritis Drug

Posted on by

x-ray image of hands

X-ray image of the hands of a patient with rheumatoid arthritis. Note that the joints at the base of the fingers are eroded — and some, like the index finger on both hands, are actually dislocated.
Copyright (2012) American College of Rheumatology.

About 1.5 million [1] people in the US suffer from rheumatoid arthritis (RA). It is a chronic illness in which the immune system, which protects us from viral and bacterial invaders, turns on our own body and viciously attacks the membranes that line our joints. The consequences can be excruciating: pain, swelling, stiffness, and decreased mobility.  Over time, the joints can become permanently contorted, as in this X-ray image.

There are several RA medications on the market, but I want to tell you about a new one called tofacitinib, a pill which the FDA approved late last year [2]. The drug works by targeting a protein called Janus kinase 3, which was discovered by John O’Shea and colleagues here at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 20 years ago [3]. As I mentioned in a previous post it takes a really long time to go from a basic discovery to a drug—in most cases nearly 15 years. This drug has been even longer in the making! Shortly after discovering Janus kinase 3 in 1993, NIAMS researchers also revealed its role in inflammation, leading to a public-private collaboration with Pfizer that has now culminated in the approval of tofacitinib.